Zollinger-Ellison Syndrome

NEW YORK, Dec. 19, 2023 /PRNewswire/ -- The proton pump inhibitors (PPIs) market size is expected to grow by USD 807.89 million from 2023 to 2028. In addition, the momentum of the market will progress at a CAGR of 4.86% during the forecast period, according to Technavio Research. The market is categorized by Product (OTC PPIs and Prescription PPIs), Route Of Administration (Oral and Injectable), and Geography (North America, Europe, Asia, and Rest of World (ROW)). North America will contribute 36% to the growth of the global market during the forecast period. Factors such as the presence of large pharmaceutical companies that offer both branded and generic PPIs and the presence of a proper regulatory framework for the approval of new drugs in the region drive regional market growth. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read a FREE PDF Sample Report Continue Reading Technavio has announced its latest market research report titled Global Proton Pump Inhibitors (PPIs) Market 2024-2028 Company Profile: Amgen Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bausch Health Companies Inc., Bayer AG, Cipla Ltd., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson, Perrigo Co. Plc, Pfizer Inc., RedHill Biopharma Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., The Procter and Gamble Co., Zydus Lifesciences Ltd. Amgen Inc. - The company offers proton pump inhibitors such as LUMAKRAS with gastric acid-reducing agents and decreased sotorasib concentrations. To gain access to more vendor profiles available with Technavio, buy the report! Proton Pump Inhibitors (PPIs) Market: Health Analysis Proton Pump Inhibitors (PPIs) play a significant role in managing various gastrointestinal conditions, including Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease, and Gastritis, effectively suppressing acid production. Helicobacter pylori, a common bacterium, often contributes to Peptic Ulcer Disease, for which both prescription and non-prescription PPIs are used as part of the treatment regimen, ensuring comprehensive therapy against this bacterial infection. The Proton Pump Inhibitor Market showcases a diverse range of medications, including FDA-approved and generic PPIs, aiming to alleviate symptoms associated with acid-related disorders like Heartburn, Erosive Esophagitis, and NSAID-Induced Ulcers. Understanding the potential side effects of Proton Pump Inhibitors is crucial, as they are associated with complications such as Duodenal Ulcers, necessitating careful consideration of their usage and monitoring for optimal gastrointestinal health. Heartburn, often associated with Acid-related Disorders, manifests as a burning sensation in the chest due to stomach acid reflux into the esophagus. This common symptom occurs post-meals, triggered by specific foods or lying down, contributing significantly to Acid-related Disorders' discomfort. Managing heartburn involves dietary modifications, maintaining an upright posture after eating, and utilizing medications to mitigate stomach acid production. Chronic heartburn, if left unaddressed, may lead to erosive esophagitis or Barrett's esophagus, highlighting its role within Acid-related Disorders and emphasizing the need for prompt intervention to alleviate symptoms and prevent complications. Proton Pump Inhibitors (PPIs) Market: Segmentation Analysis The OTC PPIs segment will be significant during the forecast period. The products in this segment are defined as medicines that are sold directly to patients or consumers without a prescription from a healthcare professional. Furthermore, the availability of OTC PPIs provides patients with an option for self-medication and reduces the financial burden associated with medication treatment. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report These six medications—Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole, and Dexlansoprazole—belong to the class of proton pump inhibitors, commonly prescribed to treat various gastrointestinal conditions by reducing stomach acid production. Each drug within this group exhibits distinct pharmacokinetic properties and efficacy profiles, catering to individual patient needs for managing acid-related disorders. "Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio Proton Pump Inhibitors (PPIs) Market: Driver & Trend: Driver Reformulation of drugs Growth in prescription rate Strong prevalence of gastroesophageal reflux disease Reformulation of drugs drives market growth. It provides an opportunity to grab patent term extensions, which can delay the entry of generic versions into the market. The availability of two dosage forms, NEXIUM 10 mg and 20 mg, will increase the consumption of the drug for various indications, particularly acid-related diseases, in both children aged one year and above the older patients with difficulty in swallowing. The rising prevalence of obesity is a leading market trend. Identify key trends, drivers, and challenges in the market. Download a sample report to gain access to this information. Unraveling Therapeutic Efficacy and Potential Complications in Gastrointestinal Health The Proton Pump Inhibitors (PPIs) Market comprises an extensive range of medications tailored to manage diverse acid-related disorders like Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease, and Gastritis. FDA-approved prescription PPIs play a significant role in treating conditions such as Zollinger-Ellison Syndrome and NSAID-Induced Ulcers, contributing significantly to gastrointestinal health and acid suppression. It's essential to recognize that both non-prescription and generic PPIs exist within this market, each exhibiting distinct efficacy profiles and potential side effects, including complications associated with prolonged use such as erosive esophagitis. Understanding the complexities of these medications is crucial for addressing various conditions and ensuring patient well-being amid the dynamic landscape of Proton Pump Inhibitors (PPIs) Market. Related Reports: The tyrosine kinase inhibitors market is estimated to grow at a CAGR of 8.93% between 2022 and 2027. The market size is forecasted to increase by USD 24.12 billion. The global PARP (poly ADP-ribose polymerase) inhibitors market size is estimated to grow by USD 5,555.99 million at a CAGR of 13.25% between 2023 and 2028. What are the key data covered in this proton pump inhibitors (PPIs) market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the proton pump inhibitors (PPIs) market between 2023 and 2028. Precise estimation of the proton pump inhibitors (PPIs) market size and its contribution to the market in focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the proton pump inhibitors (PPIs) market across North America, Europe, Asia, and ROW A thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of proton pump inhibitors (PPIs) market vendors. ToC: Executive Summary Market Landscape Market Sizing Historic Market Sizes Five Forces Analysis Market Segmentation by Product Market Segmentation by Route of Administration Market Segmentation by Geography Customer Landscape Geographic Landscape Drivers, Challenges, & Trends Company Landscape Company Analysis Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

GSK has said it welcomed the decision from The British Columbia Supreme Court to dismiss a proposed class action on behalf of Zantac (ranitidine) users in Canada, who claimed the drug or other medicines containing ranitidine increased their risk of cancer. The drugmaker and several other companies, including Pfizer, Boehringer and Sanofi, have been facing thousands of lawsuits around the world alleging that the medicines feature the carcinogen N-nitrosodimethylamine (NDMA) that caused cancer. In its ruling, the court said: “Given the uncontroverted evidence that neither ranitidine nor NDMA are reliably associated with increased cancer risk, and the absence of evidence that ranitidine or NDMA cause cancer in humans, the plaintiff has failed to raise a bona fide triable issue regarding injury due to the ingestion and/or purchase of ranitidine.” GSK has continued to maintain that the drug does not cause cancer. It said in a statement: "Since 2019 there have been 13 peer-reviewed epidemiological studies conducted looking at human data regarding the use of ranitidine. "The decision recognises that after more than three years of extensive study, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk for any type of cancer." The company added that it will continue to “vigorously defend” proposed class actions by ranitidine users that have been filed in Ontario and Quebec, as well as individual actions filed by ranitidine users in Canada. Ranitidine, originally marketed by GSK, was first approved in 1983 and became the world's best selling medicine in 1988. The drug decreases stomach acid production and is commonly used to treat conditions including peptic ulcer disease, gastroesophageal reflux disease and Zollinger–Ellison syndrome. In April 2020, ranitidine was withdrawn from the US market and suspended in the EU and Australia over growing concerns over the presence of NDMA. The dismissal from the Canadian court comes just over a month after Johnson & Johnson offered $8.9bn to resolve the tens of thousands of lawsuits it faces in North America that claim its talc-based products cause cancer.

TORONTO, Oct. 18, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) today announced that the Food and Drug Administration (FDA) has accepted for filing its abbreviated new drug application (ANDA) for a generic version of Protonix® (delayed release pantoprazole sodium). Protonix inhibits gastric acid secretion and is prescribed for the short-term treatment of conditions such as stomach ulcers associated with gastroesophageal reflux disease as well as the long term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome. Sales of pantoprazole sodium delayed-release tablets in the United States were approximately $1.8 billion in 2009.